공간 오믹스 시장 규모, 점유율, 동향 분석 보고서 : 기술별, 제품 유형별, 워크플로우별, 샘플 유형별, 최종 용도별, 지역별, 부문 예측(2025-2030년)

Spatial OMICS Market Growth & Trends:

The global spatial OMICS market size is estimated to reach USD 1696.5 million by 2030, expanding at a CAGR of 16.3% from 2025 to 2030, according to a new report by Grand View Research, Inc. The COVID-19 pandemic slowed down many industries worldwide. However, this market did not face the extensive negative impact of the pandemic.

Startups and well-established players continued their product development and launched novel solutions, democratized their offerings beyond innovators, and engaged in mergers & acquisitions. The spatial OMICS field originated from hyperplexed imaging; however, key players have shifted toward the development of spatial transcriptomics solutions and products.

Rapid advances in the sequencing of tissues, genes, and single cells have resulted in the emergence of spatial genomic sequencing. Spatial OMICS techniques offer quantitative gene expression data and visualization of DNA and RNA mapping within tissue sections. The development of novel technologies for spatial OMICS is anticipated to create lucrative opportunities for the fields of translational research as well as diagnostics.

The spatial genomics technology segment is expected to expand at the fastest CAGR throughout the forecast period owing to a rise in the launch of novel platforms. The integration of high-throughput solutions in transcriptomics, genomics, and proteomics studies has enabled determining the link between disease occurrence and genome position.

The instruments product held the second-largest share in 2020 owing to the launch of new automated solutions for spatial OMIC studies. For instance, in March 2021, Rebus Biosystems launched the new Rebus Esper spatial omics platform for a better understanding of tissue biology. The new integrated and automated instrument delivers quantitative single-cell, single-molecule data with subcellular resolution and spatial context by using advanced fluidics, imaging, chemistry, and bioinformatics solutions.

The fresh frozen sample type is expected to witness significant growth over the forecast period. The advantages of fresh frozen samples in proteomics are validated by several research studies. For instance, in March 2021, a study concluded that Filter Aided Sample Preparation (FASP) technique yielded 20% more protein identifications by using fresh frozen samples than formalin-fixed, paraffin-embedded (FFPE) samples.

North America held the largest share in 2020 owing to an increase in focus on translational research, rise in government support for genomics and sequencing technologies, high demand for personalized medicine, and the presence of a substantial number of translational and academic research organizations.

Spatial OMICS Market Report Highlights:

• By technology, The spatial transcriptomics segment dominated and held the largest market share of 71.7% in 2024 as most of the available products are based on mRNA analysis for positional information
• In terms of product, the consumables segment accounted for the largest market share of 56.2% in 2024, owing to high product penetration, increasing use of reagents & kits, wide product availability, and frequent purchase of consumables to run the instruments.
• Based on workflow, the instrumental analysis segment dominated the market and held the largest market share of 47.4% in 2024.
• The fresh frozen sample type is anticipated to expand at a lucrative CAGR from 2024 to 2030 as fresh frozen tissue preserves the native state of proteins and hence are adopted in spatial proteomics analysis
• On the basis of end use, the academic and translational research institutes dominated the market in 2023 owing to an increase in biomedical research in academic universities

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation & Scope
• 1.2. Segment Definitions
  • 1.2.1. Technology
  • 1.2.2. Product
  • 1.2.3. Workflow
  • 1.2.4. Sample Type
  • 1.2.5. End-use
• 1.3. Research Methodology
• 1.4. Information Procurement
• 1.5. Information or Data Analysis
  • 1.5.1. Data analysis models
• 1.6. Market Formulation & Validation
• 1.7. List of Secondary Sources
• 1.8. List of Primary Sources
• 1.9. Objectives

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Outlook
• 2.3. Competitive Insights

Chapter 3. Spatial OMICS Market Variables & Trends

• 3.1. Market Lineage Outlook
  • 3.1.1. Parent market outlook
  • 3.1.2. Related/ancillary market outlook
• 3.2. Market Dynamics
  • 3.2.1. Market driver analysis
    • 3.2.1.1. Emerging potential of spatial OMIC analysis as a cancer diagnostic tool
    • 3.2.1.2. Advent of fourth generation of sequencing (in situ sequencing)
    • 3.2.1.3. Increasing market competition due to emerging players
  • 3.2.2. Market restraint analysis
    • 3.2.2.1. Slow implementation of technology
    • 3.2.2.2. Well-established workflows for conventional omics analysis
• 3.3. Spatial OMICS Market Analysis Tools
  • 3.3.1. Industry Analysis - Porter's
  • 3.3.2. PESTEL Analysis
  • 3.3.3. COVID-19 Impact Analysis

Chapter 4. Technology Business Analysis

• 4.1. Technology Segment Dashboard
• 4.2. Global Spatial OMICS Market Technology Movement Analysis
• 4.3. Global Spatial OMICS Market Size & Trend Analysis, by Technology, 2018 to 2030 (USD Million)
• 4.4. Spatial Transcriptomics
  • 4.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
• 4.5. Spatial Genomics
  • 4.5.1. Market estimates and forecasts 2018 to 2030 (USD Million)
• 4.6. Spatial Proteomics
  • 4.6.1. Market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 5. Product Business Analysis

• 5.1. Product Segment Dashboard
• 5.2. Global Spatial OMICS Market Product Movement Analysis
• 5.3. Global Spatial OMICS Market Size & Trend Analysis, by Product, 2018 to 2030 (USD Million)
• 5.4. Instruments
  • 5.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.4.2. By Mode
    • 5.4.2.1. Automated
      • 5.4.2.1.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 5.4.2.2. Semi-automated
      • 5.4.2.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 5.4.2.3. Manual
      • 5.4.2.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.4.3. By Type
    • 5.4.3.1. Sequencing Platforms
      • 5.4.3.1.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 5.4.3.2. IHC
      • 5.4.3.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 5.4.3.3. Microscopy
      • 5.4.3.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 5.4.3.4. Flow Cytometry
      • 5.4.3.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 5.4.3.5. Mass Spectrometry
      • 5.4.3.5.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 5.4.3.6. Others
      • 5.4.3.6.1. Market estimates and forecasts 2018 to 2030 (USD Million)
• 5.5. Consumables
  • 5.5.1. Market estimates and forecasts 2018 to 2030 (USD Million)
• 5.6. Software
  • 5.6.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.6.2. Bioinformatics tools
    • 5.6.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.6.3. Imaging tools
    • 5.6.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.6.4. Storage and management databases
    • 5.6.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 6. Workflow Business Analysis

• 6.1. Workflow Segment Dashboard
• 6.2. Global Spatial OMICS Market Workflow Movement Analysis
• 6.3. Global Spatial OMICS Market Size & Trend Analysis, by Workflow, 2018 to 2030 (USD Million)
• 6.4. Sample Preparation
  • 6.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
• 6.5. Instrumental Analysis
  • 6.5.1. Market estimates and forecasts 2018 to 2030 (USD Million)
• 6.6. Data Analysis
  • 6.6.1. Market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 7. Sample Type Business Analysis

• 7.1. Sample Type Segment Dashboard
• 7.2. Global Spatial OMICS Market Sample Type Movement Analysis
• 7.3. Global Spatial OMICS Market Size & Trend Analysis, by Sample Type, 2018 to 2030 (USD Million)
• 7.4. FFPE
  • 7.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
• 7.5. Fresh Frozen
  • 7.5.1. Market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 8. End-use Business Analysis

• 8.1. End Use Segment Dashboard
• 8.2. Global Spatial OMICS Market End Use Movement Analysis
• 8.3. Global Spatial OMICS Market Size & Trend Analysis, by End Use, 2018 to 2030 (USD Million)
• 8.4. Academic & Translational Research Institutes
  • 8.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
• 8.5. Pharmaceutical and Biotechnology Companies
  • 8.5.1. Market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 9. Regional Business Analysis

• 9.1. Regional Market Share Analysis, 2024 & 2030
• 9.2. Regional Market Dashboard
• 9.3. North America
  • 9.3.1. North America market estimates and forecasts 2018 to 2030 (USD Million)
  • 9.3.2. U.S.
    • 9.3.2.1. Key country dynamics
    • 9.3.2.2. Regulatory framework
    • 9.3.2.3. Competitive scenario
    • 9.3.2.4. U.S. market estimates and forecasts 2018 to 2030 (USD Million)
  • 9.3.3. Canada
    • 9.3.3.1. Key country dynamics
    • 9.3.3.2. Regulatory framework
    • 9.3.3.3. Competitive scenario
    • 9.3.3.4. Canada market estimates and forecasts 2018 to 2030 (USD Million)
  • 9.3.4. Mexico
    • 9.3.4.1. Key country dynamics
    • 9.3.4.2. Regulatory framework
    • 9.3.4.3. Competitive scenario
    • 9.3.4.4. Mexico market estimates and forecasts 2018 to 2030 (USD Million)
• 9.4. Europe
  • 9.4.1. Europe market estimates and forecasts 2018 to 2030 (USD Million)
  • 9.4.2. UK
    • 9.4.2.1. Key country dynamics
    • 9.4.2.2. Regulatory framework
    • 9.4.2.3. Competitive scenario
    • 9.4.2.4. UK market estimates and forecasts 2018 to 2030 (USD Million)
  • 9.4.3. Germany
    • 9.4.3.1. Key country dynamics
    • 9.4.3.2. Regulatory framework
    • 9.4.3.3. Competitive scenario
    • 9.4.3.4. Germany market estimates and forecasts 2018 to 2030 (USD Million)
  • 9.4.4. France
    • 9.4.4.1. Key country dynamics
    • 9.4.4.2. Regulatory framework
    • 9.4.4.3. Competitive scenario
    • 9.4.4.4. France market estimates and forecasts 2018 to 2030 (USD Million)
  • 9.4.5. Italy
    • 9.4.5.1. Key country dynamics
    • 9.4.5.2. Regulatory framework
    • 9.4.5.3. Competitive scenario
    • 9.4.5.4. Italy market estimates and forecasts 2018 to 2030 (USD Million)
  • 9.4.6. Spain
    • 9.4.6.1. Key country dynamics
    • 9.4.6.2. Regulatory framework
    • 9.4.6.3. Competitive scenario
    • 9.4.6.4. Spain market estimates and forecasts 2018 to 2030 (USD Million)
  • 9.4.7. Norway
    • 9.4.7.1. Key country dynamics
    • 9.4.7.2. Regulatory framework
    • 9.4.7.3. Competitive scenario
    • 9.4.7.4. Norway market estimates and forecasts 2018 to 2030 (USD Million)
  • 9.4.8. Sweden
    • 9.4.8.1. Key country dynamics
    • 9.4.8.2. Regulatory framework
    • 9.4.8.3. Competitive scenario
    • 9.4.8.4. Sweden market estimates and forecasts 2018 to 2030 (USD Million)
  • 9.4.9. Denmark
    • 9.4.9.1. Key country dynamics
    • 9.4.9.2. Regulatory framework
    • 9.4.9.3. Competitive scenario
    • 9.4.9.4. Denmark market estimates and forecasts 2018 to 2030 (USD Million)
• 9.5. Asia Pacific
  • 9.5.1. Asia Pacific market estimates and forecasts 2018 to 2030 (USD Million)
  • 9.5.2. Japan
    • 9.5.2.1. Key country dynamics
    • 9.5.2.2. Regulatory framework
    • 9.5.2.3. Competitive scenario
    • 9.5.2.4. Japan market estimates and forecasts 2018 to 2030 (USD Million)
  • 9.5.3. China
    • 9.5.3.1. Key country dynamics
    • 9.5.3.2. Regulatory framework
    • 9.5.3.3. Competitive scenario
    • 9.5.3.4. China market estimates and forecasts 2018 to 2030 (USD Million)
  • 9.5.4. India
    • 9.5.4.1. Key country dynamics
    • 9.5.4.2. Regulatory framework
    • 9.5.4.3. Competitive scenario
    • 9.5.4.4. India market estimates and forecasts 2018 to 2030 (USD Million)
  • 9.5.5. Australia
    • 9.5.5.1. Key country dynamics
    • 9.5.5.2. Regulatory framework
    • 9.5.5.3. Competitive scenario
    • 9.5.5.4. Australia market estimates and forecasts 2018 to 2030 (USD Million)
  • 9.5.6. South Korea
    • 9.5.6.1. Key country dynamics
    • 9.5.6.2. Regulatory framework
    • 9.5.6.3. Competitive scenario
    • 9.5.6.4. South Korea market estimates and forecasts 2018 to 2030 (USD Million)
  • 9.5.7. Thailand
    • 9.5.7.1. Key country dynamics
    • 9.5.7.2. Regulatory framework
    • 9.5.7.3. Competitive scenario
    • 9.5.7.4. Thailand market estimates and forecasts 2018 to 2030 (USD Million)
• 9.6. Latin America
  • 9.6.1. Latin America market estimates and forecasts 2018 to 2030 (USD Million)
  • 9.6.2. Brazil
    • 9.6.2.1. Key country dynamics
    • 9.6.2.2. Regulatory framework
    • 9.6.2.3. Competitive scenario
    • 9.6.2.4. Brazil market estimates and forecasts 2018 to 2030 (USD Million)
  • 9.6.3. Argentina
    • 9.6.3.1. Key country dynamics
    • 9.6.3.2. Regulatory framework
    • 9.6.3.3. Competitive scenario
    • 9.6.3.4. Argentina market estimates and forecasts 2018 to 2030 (USD Million)
• 9.7. MEA
  • 9.7.1. MEA market estimates and forecasts 2018 to 2030 (USD Million)
  • 9.7.2. South Africa
    • 9.7.2.1. Key country dynamics
    • 9.7.2.2. Regulatory framework
    • 9.7.2.3. Competitive scenario
    • 9.7.2.4. South Africa market estimates and forecasts 2018 to 2030 (USD Million)
  • 9.7.3. Saudi Arabia
    • 9.7.3.1. Key country dynamics
    • 9.7.3.2. Regulatory framework
    • 9.7.3.3. Competitive scenario
    • 9.7.3.4. Saudi Arabia market estimates and forecasts 2018 to 2030 (USD Million)
  • 9.7.4. UAE
    • 9.7.4.1. Key country dynamics
    • 9.7.4.2. Regulatory framework
    • 9.7.4.3. Competitive scenario
    • 9.7.4.4. UAE market estimates and forecasts 2018 to 2030 (USD Million)
  • 9.7.5. Kuwait
    • 9.7.5.1. Key country dynamics
    • 9.7.5.2. Regulatory framework
    • 9.7.5.3. Competitive scenario
    • 9.7.5.4. Kuwait market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 10. Competitive Landscape

• 10.1. Company Categorization
• 10.2. Strategy Mapping
• 10.3. Company position analysis, 2024
• 10.4. Company Profiles/Listing
  • 10.4.1. 10x Genomics
    • 10.4.1.1. Company overview
    • 10.4.1.2. Financial performance
    • 10.4.1.3. Product benchmarking
    • 10.4.1.4. Strategic initiatives
  • 10.4.2. Dovetail Genomics
    • 10.4.2.1. Company overview
    • 10.4.2.2. Financial performance
    • 10.4.2.3. Product benchmarking
    • 10.4.2.4. Strategic initiatives
  • 10.4.3. S2 Genomics, Inc.
    • 10.4.3.1. Company overview
    • 10.4.3.2. Financial performance
    • 10.4.3.3. Product benchmarking
    • 10.4.3.4. Strategic initiatives
  • 10.4.4. Bruker
    • 10.4.4.1. Company overview
    • 10.4.4.2. Financial performance
    • 10.4.4.3. Product benchmarking
    • 10.4.4.4. Strategic initiatives
  • 10.4.5. Bio-Techne
    • 10.4.5.1. Company overview
    • 10.4.5.2. Financial performance
    • 10.4.5.3. Product benchmarking
    • 10.4.5.4. Strategic initiatives
  • 10.4.6. Vizgen, Inc.
    • 10.4.6.1. Company overview
    • 10.4.6.2. Financial performance
    • 10.4.6.3. Product benchmarking
    • 10.4.6.4. Strategic initiatives
  • 10.4.7. Akoya Biosciences, Inc.
    • 10.4.7.1. Company overview
    • 10.4.7.2. Financial performance
    • 10.4.7.3. Product benchmarking
    • 10.4.7.4. Strategic initiatives
  • 10.4.8. Standard BioTools
    • 10.4.8.1. Company overview
    • 10.4.8.2. Financial performance
    • 10.4.8.3. Product benchmarking
    • 10.4.8.4. Strategic initiatives
  • 10.4.9. Rebus Biosystems, Inc.
    • 10.4.9.1. Company overview
    • 10.4.9.2. Financial performance
    • 10.4.9.3. Product benchmarking
    • 10.4.9.4. Strategic initiatives
  • 10.4.10. RareCyte, Inc
    • 10.4.10.1. Company overview
    • 10.4.10.2. Financial performance
    • 10.4.10.3. Product benchmarking
    • 10.4.10.4. Strategic initiatives